Revvity raised its full-year 2026 organic growth outlook to 4%-5% from 3%-4%, while also lifting margin and EPS expectations.
Revvity is expanding high-content screening instrument and reagent capacity as Opera Phenix OptIQ orders outpace near-term production, with backlog entering third-quarter 2026.
Life Sciences platforms/instrument growth guidance was raised to positive mid-single digits for full-year 2026 from low-single digits, driven by stronger orders and backlog.
Signals software product LabGistics is expected to launch in the second half of 2026, extending Revvity's AI workflow portfolio.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Revvity, Inc. and 4,900+ companies.